64544-01-0

Basic information

• Product Name: 4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-
• CAS NO: 64544-01-0
• Molecular Formula: C16H17BrClN3O3
• Mol File: 64544-01-0.mol

Chemical Properties

• CAS DataBase Reference: 4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-(64544-01-0)
• EPA Substance Registry System: 4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-(64544-01-0)

Safety Data

• Hazardous Substances Data: 64544-01-0(Hazardous Substances Data)

Upstream product

• 17518-98-8 7-bromo-6-chloro-3,4-dihydroquinazolin-4-one 
• 150812-32-1 2-amino-4-bromo-5-chlorobenzoic acid 
• 108-41-8 1-chloro-3-methylbenzene 

Downstream Products

• 17395-31-2 halofuginone hydrobromide 
• 17395-31-2 halofuginone hydrobromide 
• 17395-31-2 DIV03873 
• 17395-31-2 trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]-4(3H)-quinazolinone hydrobromide 

Relevant articles and documents

A novel synthesis of the efficient anti-coccidial drug halofuginone hydrobromide

Background: Halofuginone hydrobromide (1) is recognized as an effective drug against several species of Eimeria (E.) in poultry. In this paper, we describe a convenient and low cost preparation method for the compound, as well as primary validation of its activity. Methods: First, 7-bromo-6-chloroquinazolin-4(3H)-one (2) was prepared from m-chlorotoluene by a conventional process, and then chloroacetone was creatively introduced in two steps. Finally, halofuginone hydrobromide (1) was obtained from 7-bromo-6-chloro-3-(3-cholroacetonyl) quinazolin-4(3H)-one (4) by a four-step reaction sequence including condensation, cyclization, deprotection and isomerization. The structures of the relative intermediates and target compound were characterized by melting point, IR, MS and 1H-NMR. Besides, the protective effect of compound 1-supplemented chicken diet at doses of 6, 3 and 1.5 mg per 1 kg were evaluated on chickens infected with E. tenella, by reduction in mortality, weight loss, fecal oocyst excretion and gut pathology, respectively. Results: Halofuginone hydrobromide (1) was prepared successfully by and improved and innovative method based on traditional research. Moreover, the synthesized halofuginone hydrobromide significantly exhibited an anti-coccidial property. Conclusions: The fruitful work described in this Communication has resulted in halofuginone hydrobromide, which has a good pharmaceutical development prospects, becoming more available for large-scale production.

New synthesis process for preparing veterinary bulk drug halofuginone hydrobromide

The invention discloses a process method for preparing veterinary raw material drug halofuginone hydrobromide, and relates to the field of veterinary drugs and the technical field of drug synthesis. According to the invention, a novel process route is adopted, 7-bromo-3-(8-bromo-5-hydroxy-2-oxo-3-octenyl)-6-chloro-4 (3H)-quinazolinone is taken as a starting raw material, and the halofuginone hydrobromide is prepared through three-step reaction of ammonolysis, purification and salification, so that the problems of difficulty in obtaining raw materials, harsh reaction conditions, high cost and the like in the existing synthesis method are solved. The novel synthesis process for preparing the veterinary drug halofuginone hydrobromide is simple in process operation, low in production cost, few in steps, high in total yield, small in pollution and suitable for industrial mass production.

Novel quinazolinone

The novel product, dextrorotary 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-acetonyl]-4(3H)-quinazolinone and its non-toxic, pharmaceutically acceptable acid addition salts having anticoccidiosis activity and its preparation and use.